Effects of glucagon-like peptide-1 receptor agonists on glucose excursion and inflammation in overweight or obese type 2 diabetic patients

Figure 1 Changes in blood glucose levels before and after treatment in patients. A: Fasting blood glucose (FBG); B: 2-h postprandial blood glucose (2hPBG); C: Glycated hemoglobin (HbA1c). ^aP < 0.05; ^bP < 0.01; ^cP < 0.001.

Figure 2 Changes in blood glucose level and islet cell function of patients before and after treatment. A: 24-h mean blood glucose (MBG); B: 24-h standard deviation of blood glucose (SDBG); C: Coefficient of variation (CV%); D: Mean amplitude of glycemic excursions (MAGEs); E: Absolute mean of daily differences (MODD); F: Percentage of time (TIR) with 3.9 mmol/L < glucose < 10 mmol/L before and after treatment in the two groups. ^aP < 0.001.

Figure 3 Changes in patients’ blood lipid indexes before and after treatment in both groups. A: Total cholesterol; B: Triglycerides; C: High-density lipoprotein; D: Low-density lipoprotein. ^bP < 0.01; ^cP < 0.001.

Figure 4 Changes in inflammatory factor levels in patients before and after treatment in the two groups. A: Tumor necrosis factor-alpha (TNF-α); B: Interleukin-6 (IL-6); C: High-sensitivity C-reactive protein (hs-CRP). ^aP < 0.05; ^cP < 0.001.